Nerixia (nerindronic acid) / Lee's Pharm, Abiogen, Grunenthal, Takeda - LARVOL DELTA

Transient Osteoporosis of the Hip: Clinical and Radiological Outcomes After Combined Pharmacologic and Biophysical Therapy. (PubMed, J Clin Med) - "The aim of this study was to evaluate clinical outcomes following treatment with Neridronate, Clodronic Acid, Cholecalciferol, and pulsed electromagnetic field therapy (PEMF). Early diagnosis and timely intervention are essential to progression to osteonecrosis. A combined therapeutic approach using bisphosphonates, vitamin D, and PEMF appears effective in reducing symptoms, promoting bone healing, and ensuring good patient compliance."

Journal • Immunology • Osteoporosis • Pain • Rheumatology

A precision medicine approach to identifying patients with Complex Regional Pain Syndrome Type 1 who may benefit from neridronate (ASRA-FALL 2025) - P3 | "• Overall, 206 participants across 3 trials had CRPS-1 at baseline (Table 1). • Trial KF7013-02 Red and/or warm affected limb subgroup (scored as yes/no): • The analysis included participants with CRPS-1 and available Week 12 pain intensity scores with (n=12) and without (n=19) physical exam findings of affected limb redness and/or warmth prior to receiving study treatment. • Treatment with neridronate in participants with a red and/or warm affected limb at baseline showed a greater LS mean difference12week in average pain intensity of -2.11 (95% CI: -3.99, -0.23; nominal p=0.03; Table 2) compared to those without these inflammatory signs at baseline (-1.14; 95% CI: -1.92, -0.36; nominal p=0.004; Table 2)."

Clinical • Inflammation • Musculoskeletal Pain • Pain

Beyond Averages: Informing Clinical Decision Making in the Pharmacologic Treatment of CRPS-1 using Bayesian Network Meta-Analysis (ASRA-FALL 2025) - "Across 17 trials, a total of 375 subjects were randomized to active treatment arms, and 379 to placebo. The evidence network was a placebo-anchored star (Figure 1), with edge thickness proportional to the number of trials per comparison. Treatments included: Neridronate: n=160 Ketamine: n=79 Alendronate: n=59 Pamidronate: n=48 Gabapentin: n=46 Corticosteroids: n=41 Mannitol: n=41 IVIG: n=13 Scavengers / Magnesium Sulfate: n=257 Ranked posterior probabilities of achieving a ≥20 mm VAS pain reduction, alongside average placebo-adjusted effects and 95% credible intervals, are summarized in Table 2."

Late-breaking abstract • Retrospective data • Musculoskeletal Pain

Pivotal phase 3 trial of neridronate in Complex Regional Pain Syndrome Type 1: CRPS-RISE study design and methodology (ASRA-FALL 2025) - P3 | "For example: • Analgesics, such as acetaminophen, nonsteroidal anti-inflammatory drugs, opioids ≤ 45 morphine equivalents/day, and neuropathic therapies (e.g., gabapentinoids) • Physical therapy, occupational therapy, rehabilitation modalities, psychological or psychiatric modalities Rescue Treatment • Rescue medications are permitted to treat pain and include: • 1st line: Acetaminophen, with a total daily dose ≤ 4 grams/day • 2nd line: For moderate to severe pain (e.g., > 4 on 0-10 scale) that persist 30 min after acetaminophen was taken as rescue, oxycodone 5 mg immediate release may be taken (up to 4 times/day) Prophylaxis of Acute Phase Reaction • Short-term use of IV bisphosphonates, as in the case of this trial, is generally well-tolerated, with the most common adverse event expected to be acute phase reaction...• Given the progressive nature of CRPS and the different subtypes, it is important to consider a precision medicine approach that targets the right..."

P3 data • CNS Disorders • Musculoskeletal Pain • Pain • Psychiatry • Rare Diseases • Sleep Disorder

Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1 (SSIEM 2023) - No abstract available

Genetic Disorders

Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1 (SSIEM 2023) - No abstract available

Genetic Disorders

Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1 (SSIEM 2023) - No abstract available

Genetic Disorders

Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1 (SSIEM 2023) - "Consistently, in the media of the same osteoclast cultures, we demonstrated a significant increase in caspase- 3 levels. CONCLUSION Our findings support the idea that CK-BB levels increase in the serum of OI-treated patients."

Genetic Disorders • CSF1

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) (clinicaltrials.gov) - P3 | N=270 | Not yet recruiting | Sponsor: Ambros Therapeutics, Inc.

New P3 trial • Musculoskeletal Pain • Pain

The Warm Phase of CRPS Type-1: Is It Time to Review the Budapest Criteria? (PubMed, Diagnostics (Basel)) - "Therefore, a correct clinical history and, if needed, further radiological studies and laboratory tests should be performed to avoid a false diagnosis. In this paper, the "Bone Marrow Edema Diagnosis and Therapeutic Treatment" Italian Group (GEODEIT) proposes a revision of Budapest's criteria to make them more meaningful and effective in reaching a correct and quick diagnosis of the disease."

Journal • Immunology • Musculoskeletal Pain • Pain

Detecting rapid elevations in blood pressure using a novel pulse arrival time and machine learning technique. (PubMed, Am J Physiol Heart Circ Physiol) - "The data supports that the AHDP successfully detected laboratory-simulated elevated BP. The further development of the AHDP is expected to lead to effective hypertensive crises detection systems for wearable devices."

Journal • Cardiovascular • Hypertension

Isolated Navicular Algodystrophy and Abnormal Capillaroscopic Pattern in a 50-year-old Smoker: A Possible Microvascular Connection. (PubMed, Mediterr J Rheumatol) - "The patient underwent intramuscular treatment with neridronate, which resulted in full symptomatic remission and radiological resolution at three months. This case highlights the potential role of microvascular dysfunction in algodystrophy and suggests that NVC may serve as a valuable diagnostic tool in patients with unexplained regional pain syndromes. Future studies are required to establish a definitive causal relationship."

Journal • Immunology • Musculoskeletal Pain • Pain

Bone marrow edema in osteoarthritis and bone trauma. Diagnose and treatment. (PubMed, Clin Ter) - "Bisphosphonates (BPs), in particular Neridronate (NER) and Clodronate (CLO) are, at the moment, the most studied treatments for BME. However other cares with hyperbaric oxygen treatment or pulse electromagnetic fields can be also used in TE. In this review GEODEIT (Gruppo Edema Osseo, Diagnosi e Interventi Terapeutici), an italian scientific society discusses about diagnose and treatment of both, OA and TE conditions."

Journal • Review • Hematological Disorders • Immunology • Mood Disorders • Osteoarthritis • Pain • Rheumatology

A Systematic Review on the Efficacy of Bisphosphonates on Osteogenesis Imperfecta. (PubMed, Cureus) - "This manuscript examines the comparative effectiveness of alendronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronic acid on fracture rate reduction, increases in lumbar spine (LS) bone mineral density (BMD), and adverse effects compared to placebos and each other. This analysis highlighted the efficacy and safety profiles of bisphosphonates in the treatment of OI. Neridronate and olpadronate were highly effective in reducing fracture risk and rates, and olpadronate demonstrated superior efficacy in reducing fracture rates. Future research should focus on large, diverse samples, detailed fracture and BMD data, and comparisons across multiple bisphosphonates to refine treatment strategies."

Journal • Review • Gastrointestinal Disorder • Genetic Disorders • Musculoskeletal Diseases • Orthopedics

Bone mineral density is associated with pre-treatment pain levels of complex regional pain syndrome type 1 and predicts the response to N-containing bisphosphonates. (PubMed, Clin Exp Rheumatol) - "Lower BMD was associated with greater CRPS severity and better response to treatment. These findings support the roleof bone in CRPS pathogenesis and suggest that DXA-derived Z-scores may help identify patients most likely to benefit from bisphosphonates."

Journal • Observational data • Musculoskeletal Pain • Osteoporosis • Pain

Assessment and treatment of osteoporosis in a patient with a neurodevelopmental disorder caused by a RNU4-2 pathogenic variant (ReNU syndrome). (PubMed, JBMR Plus) - "Treatment of the severe osteoporosis was initiated with neridronate...RNU4-2 pathogenic variants underlie a NDD with multisystemic involvement, including skeletal abnormalities. Therefore, this case not only underlines the relevance of osteologic assessment and therapy in individuals with NDDs, but also highlights the necessity of future research efforts to elucidate the bone pathologies in ReNU syndrome."

Journal • CNS Disorders • Developmental Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psychiatry • Rheumatology

Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction. (PubMed, Front Endocrinol (Lausanne)) - "At the age of 5 years and 6 months, intravenous neridronate was started every 3 months with a partial improvement of bone pain and bone deformities. Nonetheless, a partial progression of FD was documented on periodic X-rays. Burosumab showed beneficial effects on bone tissue metabolisms in our patient without significant adverse effects but did not change FD course."

Journal • Review • Genetic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pediatrics • Renal Disease • FGF23

Transient osteoporosis of the hip and fatty liver disease: Case report and pathogenic hypothesis. (PubMed, J Int Med Res) - "The patient underwent a treatment regimen involving 16 days of intramuscular neridronate along with physical therapy. At the 3- and 6-month follow-ups, he showed significant improvements in both clinical symptoms and radiological findings. In our study, we propose, for the first time, a potential association between liver disorders, specifically non-alcoholic fatty liver disease, and the onset of transient osteoporosis of the hip, exploring the possible pathophysiological mechanisms connecting these two conditions and discuss the rationale for both pharmacological and non-pharmacological treatments."

Journal • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatotic Liver Disease • Musculoskeletal Pain • Osteoporosis • Pain • Rheumatology

Investigating the Competitive Adsorption of Polymer-Bisphosphonate Ligands on Lanthanide Nanoparticles. (PubMed, Langmuir) - "All polymers had a neridronate (Ner) end group that provided a bisphosphonate to promote strong binding to the lanthanide NP (LnNP) surface...Another set of surprising results is that when methoxy-PEG-Ner samples competed with PSBMA-Ner, more PSBMA than PEG became bound to the surface. However, when the azide-PEG-Ner samples competed with PSBMA-Ner, more PEG than PSBMA became bound to the surface."

Journal

An unresolving painful condition following a trivial peripheral fracture. (PubMed, J Bone Miner Res) - "However, they were immediately resolved by prompt neridronate infusion. No further complaints have been reported during the next 3 yr follow-up."

Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Benign Evolution of Complex Regional Pain Syndrome (CRPS) Type 1 in Patients Treated with Intravenous Neridronate: A Single-Center Real-Life Experience. (PubMed, Pharmaceuticals (Basel)) - "Our real-life data indicate that early treatment with neridronate leads to substantial benefits in patients affected by CRPS type 1. The strongest responses are seen in young patients, males, and those with lower limb involvement."

Journal • CNS Disorders • Depression • Fatigue • Musculoskeletal Pain • Pain • Psychiatry • Sleep Disorder

Is CRPS-1 a Chronic Disabling Disease? A Long-term, Real-Life Study on Patients Treated With Neridronate. (PubMed, Clin Med Insights Arthritis Musculoskelet Disord) - "Predictors of residual disability were younger age (odds ratio [OR]: 0.77, 95% CI: 0.63-0.93; P = .012) and delay between disease onset and treatment (OR: 1.45, 95% CI: 1.13-1.96; P = .004). In this real-life study, neridronate parenteral treatment provided a full recovery of CRPS-1 in over 3 quarters of patients, provided they are treated early."

Journal • Musculoskeletal Pain • Pain

Efficacy and safety of neridronate in paediatric type I complex regional pain syndrome: a multicentre experience. (PubMed, Clin Exp Rheumatol) - "Our data suggest that in children as in adults with CRPS I, neridronate may represent an effective and safe treatment option, particularly in those who do not respond to other pain treatments."

Journal • Musculoskeletal Pain • Pain • Pediatrics • Rheumatoid Arthritis • Rheumatology

Testing a Nanoparticle Reagent for Imaging Mass Cytometry. (PubMed, Biomacromolecules) - "A two-step ligand exchange was used to coat NP surfaces with either methoxy-PEG2K-neridronate (PEG-Ner) and/or poly(sulfobetaine methacrylate)-neridronate (PSBMA-Ner)...However, breast cancer tissue samples showed increased NSB at titers above 2 × 1010 NPs/mL. Reduced NSB with mixed PEG-Ner and PSBMA-Ner coatings opens the door for using heterobifunctional PEGs for the development of NP conjugates with bioaffinity agents, enabling more sensitive and specific MC analyses."

Journal • Breast Cancer • Oncology • Solid Tumor

Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome. (PubMed, Clin Exp Rheumatol) - "In this real-life study neridronate was associated with rapid and progressive improvement of symptoms of CRPS which was maintained up to 3 years of follow-up. The predictors of excellent response were early response, lower limb localisation, absence of predisposing events and male gender."

Journal • Musculoskeletal Pain • Pain